Business, energy, technology, markets and global industry news from Business News Today

relapsed refractory multiple myeloma

PharmaDeviceNews relapsed refractory multiple myeloma
Pharma & Biotech

J&J’s Tecvayli-Darzalex Faspro combination approved for myeloma after MajesTEC-3 Phase 3 results

FDA approves J&J's teclistamab plus daratumumab for relapsed myeloma from second line. Analyse the MajesTEC-3 data, safety profile, and what this changes for treatment.

Read More
Pharma & Biotech

Starton Therapeutics advances STAR-LLD as delivery innovation in multiple myeloma

Starton Therapeutics advances STAR-LLD in Phase 2a. Explore how continuous lenalidomide delivery could reshape multiple myeloma care.

Read More
Pharma & Biotech

Bristol Myers Squibb pushes CELMoD frontier as FDA accepts iberdomide NDA in relapsed multiple myeloma

FDA accepts Bristol Myers Squibb’s iberdomide NDA for relapsed multiple myeloma. Find out what this CELMoD filing could change next.

Read More